Liver transplant patients may dodge kidney failure with simple drug infusion
NCT ID NCT04592744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a drug called angiotensin 2 during liver transplant surgery can prevent acute kidney injury, a common and serious complication. About 30 adults with end-stage liver disease will be randomly assigned to receive either the drug plus standard care or standard care alone during their operation. Researchers will track kidney function and complications for up to 28 days after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- A simple sensor on the back could warn of kidney danger during heart surgery
- Can immune cells predict herpesvirus danger in transplant patients?
- Can a helping hand ease the burden of pediatric liver transplants?
- Can a helping hand ease the leap to adult transplant care?
- Can a common blood thinner be safe for ICU patients with liver issues?